Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 4

Trial readouts

Oral semaglutide cognition cohort

A retrospective cohort linked oral semaglutide with fewer new cognitive-impairment cases than DPP-4 inhibitors, but it cannot prove prevention.

28 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide and a thyroid cancer case

A papillary thyroid cancer case during semaglutide use cannot establish causation, and larger human studies have not confirmed excess risk.

28 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide and retinal vascular events

A scoping review found more retinal vascular events reported with semaglutide than placebo, but the events were rare and estimates remain uncertain.

28 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

An oral semaglutide emulsion in rats

A lipid-based semaglutide formulation improved cell transport and glucose measures in diabetic rats, but it has not been tested in people.

28 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide, Low Testosterone, Nine Men

An exploratory study of nine men ties semaglutide to shifted DNA methylation in obesity-related low testosterone, and it is far too small to prove anything.

27 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

BPC-157 and TB-500, examined separately

BPC-157 and TB-500 get treated as a matched set online, but they are different molecules with separate, mostly animal-only evidence and neither is approved.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 Drugs and Kidney Outcomes in CKD

Thirteen GLP-1 receptor agonist trials pooled in chronic kidney disease show fewer heart and kidney events, with semaglutide topping an exploratory ranking.

26 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Tirzepatide May Ease Beta-Cell Hypoxia

A mouse and cell study finds tirzepatide, GLP-1, and GIP suppress high-glucose-induced beta-cell hypoxia through a cAMP/PKA pathway.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Missed Doses of Oral vs Weekly Semaglutide

A Novo Nordisk research letter models what missing doses does to drug levels for oral semaglutide versus once-weekly GLP-1 injections.

26 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

PT-141 for male ED: what the FDA says

PT-141 is FDA-approved for low sexual desire in premenopausal women, not male erectile dysfunction, and the off-label male use has far thinner evidence.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

An RNA Therapy for Muscle Loss on GLP-1s

In mice, a new RNA-based therapy paired with semaglutide preserved more lean mass than semaglutide alone, though it remains far from human use.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide in Children: England's Data

A corrected conference abstract from 35 English specialist clinics reports how 406 children and young people fared on semaglutide.

26 Sept 2026 · PeptideMethods Editorial Team · 5 min read